Last reviewed · How we verify
Octreotide (drug)
Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels to inhibit the secretion of various hormones and reduce blood flow to tumors.
Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels to inhibit the secretion of various hormones and reduce blood flow to tumors. Used for Acromegaly, Variceal bleeding in portal hypertension, Carcinoid syndrome.
At a glance
| Generic name | Octreotide (drug) |
|---|---|
| Also known as | Octreotide acetate, Octreotide and 1-O-n-Dodecyl-b-D-Maltoyranoside (DDM) (Intravail®), Sandostatin®, Somatostatin analogue |
| Sponsor | Lahore General Hospital |
| Drug class | Somatostatin analog |
| Target | Somatostatin receptors (SSTR2, SSTR5) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Octreotide mimics the natural hormone somatostatin by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine tumor cells and vascular tissue. This binding suppresses the release of growth hormone, insulin, glucagon, and other hormones, while also causing vasoconstriction that reduces blood supply to tumors. These dual effects make it useful in controlling hormone-related symptoms and slowing tumor growth in neuroendocrine malignancies.
Approved indications
- Acromegaly
- Variceal bleeding in portal hypertension
- Neuroendocrine tumors (carcinoid syndrome, VIPoma, gastrinoma)
- Thyroid storm
Common side effects
- Abdominal pain/discomfort
- Diarrhea
- Nausea
- Gallstone formation (cholelithiasis)
- Hyperglycemia
- Injection site pain
- Headache
Key clinical trials
- Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome (PHASE2)
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (PHASE3)
- Hoffa's Fat Pad Impingement (HFPI) (PHASE4)
- Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome (PHASE2)
- Octreotide Microspheres for Preventing Pancreatic Fistula (PHASE3)
- Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome (NA)
- Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen (PHASE3)
- Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |